House Bill 3810
118th Congress(2023-2024)
Drug Origin Transparency Act of 2023
Introduced
Introduced in House on Jun 5, 2023
Origin Chamber
House
Type
Bill
Bill
The primary form of legislative measure used to propose law. Depending on the chamber of origin, bills begin with a designation of either H.R. or S. Joint resolution is another form of legislative measure used to propose law.
Bill Number
3810
Congress
118
Policy Area
Health
Health
Primary focus of measure is science or practice of the diagnosis, treatment, and prevention of disease; health services administration and funding, including such programs as Medicare and Medicaid; health personnel and medical education; drug use and safety; health care coverage and insurance; health facilities. Measures concerning controlled substances and drug trafficking may fall under Crime and Law Enforcement policy area.
No House votes have been held for this bill.
Summary
Drug Origin Transparency Act of 2023
This bill requires drug manufacturers to report on the suppliers of ingredients used in their products.
Specifically, drug manufacturers must report information relating to the supply chain of their products, including the suppliers of active ingredients and the amount of drugs that are manufactured using those ingredients. Drug manufacturers must also include information about the manufacturers of ingredients on the labels of their products.
June 5, 2023
Sort by most recent
06/09/2023
Referred to the Subcommittee on Health.
06/05/2023
Referred to the House Committee on Energy and Commerce.
06/05/2023
Introduced in House
Public Record
Record Updated
Jun 28, 2024 8:21:54 PM